Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc.

Core Insights - Arcutis Biotherapeutics has signed a co-promotion agreement with Kowa Pharmaceuticals America to market ZORYVE (roflumilast) in primary care and pediatric practices, aiming to reach a broader patient base for conditions like plaque psoriasis, seborrheic dermatitis, and atopic dermatitis [1][2] - The partnership is expected to enhance ZORYVE's market access, targeting the 7.4 million individuals treated outside dermatology offices, while Arcutis will continue to focus on dermatology specialists [1][2] - Kowa will promote ZORYVE as a core product, leveraging its established relationships in primary care, and will receive a commission on sales, although financial terms were not disclosed [2] Company Overview - Arcutis Biotherapeutics is a commercial-stage medical dermatology company focused on innovations for immune-mediated dermatological diseases, with a portfolio that includes three FDA-approved products [6] - Kowa Pharmaceuticals America specializes in primary care diseases and aims to successfully commercialize its pharmaceutical products while addressing unmet patient needs [8] Product Indications - ZORYVE cream (0.3%) is indicated for the topical treatment of plaque psoriasis in patients aged 6 and older [3] - ZORYVE cream (0.15%) is indicated for mild to moderate atopic dermatitis in patients aged 6 and older [3] - ZORYVE foam (0.3%) is indicated for seborrheic dermatitis in patients aged 9 and older [3]